
KRBPQ
Healthcare · Biotechnology · $265 market cap
$0.00010.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 14, 2025 | Time not confirmed | — | 13.13 | — |
| Nov 29, 2024 | Time not confirmed | — | -6.12 | — |
| Aug 9, 2024 | Time not confirmed | — | -5.54 | — |
| May 10, 2024 | Time not confirmed | — | -5.46 | — |
| Feb 28, 2024 | Time not confirmed | — | -4.50 | — |
| Nov 13, 2023 | Time not confirmed | — | -4.28 | — |
| Aug 11, 2023 | Time not confirmed | — | -6.99 | — |
| May 12, 2023 | Time not confirmed | -0.29 | -6.17 | -2027.6% |
| Mar 29, 2023 | Time not confirmed | -0.56 | 0.00 | +100.0% |
| Nov 14, 2022 | After the close | -16.80 | -15.90 | +5.4% |
| Aug 12, 2022 | After the close | -12.30 | -16.20 | -31.7% |
| May 13, 2022 | After the close | -8.70 | -14.40 | -65.5% |
| Mar 11, 2022 | Time not confirmed | -0.26 | -0.40 | -53.8% |
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-small cell lung…
| Aug 13, 2021 | Time not confirmed | — | -0.68 | — |
| May 14, 2021 | Time not confirmed | — | -0.53 | — |
| Mar 31, 2021 | Time not confirmed | — | -0.49 | — |
| Nov 30, 2020 | Time not confirmed | — | -0.33 | — |